TABLE I.

Characteristics of Each Period

	Period 1 1/1/1984–31/8/1992	Period 2 1/9/1992–30/4/2001	Period 3 1/5/2001–31/12/2009	P-value
Number of HSCTa	41	48	47
Number of patients	40	46	44
Baseline characteristics
Males	30 (73.2%)	35 (72.9%)	31 (66%)	0.7
Median age (months) at HSCT (range)	117 (9–235)	97 (10–206)	108 (17–221)	0.48
Median time (months) from diagnosis to HSCT (range)	36 (4–114)	34 (5–122)	23 (4–80)	<0.01
Remission status
CR1	4 (9.8%)	4 (8.3%)	15 (31.9%)	0.003
CR2	23 (56.1%)	35 (72.9%)	25 (53.2%)	0.108
CR3	12 (29.3%)	7 (14.6%)	5 (10.6%)	0.058
CR4	1 (2.4%)	1 (2.1%)	0	0.59
Not documented	0	0	2 (4.3%)	N/Ah
Persistent disease	1 (2.4%)	1 (2.1%)	0	N/Ah
Radiotherapy administered prior to HSCT conditioning	12 (29.3%)	11 (22.9%)	1 (2.13%)	<0.01
Graft type
MSDb	27 (65.9%)	20 (41.7%)	15 (31.9%)	0.02
UCTc	0	8 (16.7%)	21 (44.7%)	<0.01
MUDd	2 (4.9%)	12 (25%)	10 (21.3%)	0.033
FRDe (Haplo/MMSDf)	12 (29.3%)	8 (16.7%)	1 (2.1%)	0.002
T cell depletion	8 (19.51%)	16 (33.3%)	10 (21.3%)	0.25
Conditioning type
TBI-based conditioning	15 (36.6%)	31 (64.6%)	45 (95.7%)	<0.01
Chemotherapy alone	26 (63.4%)	17 (35.4%)	2 (2.1%)	<0.01
CMV status (donor/recipient)
D−/R−g	16 (39%)	14 (29.2%)	25 (53.2%)	0.06
D−/R+	3 (7.3%)	8 (16.7%)	11 (23.4%)	0.125
D+/R+	10 (24.4%)	16 (33.3%)	5 (10.6%)	0.03
D+/R−	9 (22%)	9 (18.8%)	6 (12.8%)	0.52
Not tested	3 (7.3%)	1 (2.1%)	0	N/Ah

^aHematopoeitic stem cell transplant

^bMatched sibling donor

^cUmbilical cord blood transplant

^dMatched unrelated donor

^eFamily-related donor

^fMismatched sibling donor

^gD−/R− denotes that pre-transplant CMV status is negative for donor, negative for recipient

^hP-value not generated as numbers for analysis are too small.